HALB (HALB) Stock Price & Analysis
HALB (HALB) rose 25.00% to USD 0 as of July 25, 2026 at 08:27 UTC, according to Nexqual real-time market data.
HALB last closed at USD 0; the session ranged USD 0–0 on volume of 450,400 shares. Market capitalization is $707,303, with a 52-week range of USD 0–0 (OID). Source: Nexqual, July 25, 2026 at 08:27 UTC.
Key Statistics (as of July 25, 2026 at 08:27 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 25.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 450,400 shares |
| Market Cap | $707,303 |
| Exchange | OID |
Technical Analysis (HALB)
Nexqual's technical model rates HALB "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 08:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.31 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (HALB)
Wall Street analysts rate HALB "None", per Nexqual as of July 25, 2026 at 08:27 UTC.
| Consensus Rating | None |
|---|
Earnings (HALB)
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Financials & Fundamentals (HALB)
| Total Revenue | $6,939 |
|---|---|
| Revenue Growth (YoY) | +6.40% |
| Gross Margin | +64.82% |
| Operating Margin | -24292.03% |
| Profit Margin | +0.00% |
| Current Ratio | 0.03 |
| Total Cash | $8,162 |
| Total Debt | $150,000 |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Financial Health Score (HALB)
Nexqual rates HALB's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 08:27 UTC.
| Growth | Solid — Revenue +6% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $8K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$1M |
| Efficiency | Mixed — No data |
Ownership (HALB)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 707.30M |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Leadership (HALB)
HALB is led by William A. Hartman (age 83), President, CEO & Chairman, per Nexqual as of July 25, 2026 at 08:27 UTC.
| President, CEO & Chairman | William A. Hartman (age 83) |
|---|---|
| COO & Director | John S. Borza AVS, MBA, PE (age 71) |
| Director & Accounting Director | Heidi H. Carl (age 54) |
| CTO & Member of the Scientific Advisory Board | Mitchell S. Felder (age 71) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TSOI | Therapeutic Solutions Internati | USD 0 | ▲ 0% |
| TPTW | TPT Global Tech, Inc. | USD 0 | ▲ 0% |
| BBRW | BREWBILT MFG INC. | USD 0 | ▲ 0% |
| KYNC | KYN Capital Group, Inc. | USD 0 | ▲ 0% |
| RGBP | Regen Biopharma, Inc. | USD 0 | ▲ 100% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:27 UTC. This page is informational and not investment advice.